Bennet R, Eriksson M, Nord CE, Zetterström R Fecal bacterial microflora of newborn infants during intensive care management and treatment with five antibiotic regimens. Pediatr Infect Dis. 1986 Sep-Oct;5(5):533-9.
Benno Y, Sawada K, Mitsuoka T The intestinal microflora of infants: composition of fecal flora in breast-fed and bottle-fed infants. Microbiol Immunol. 1984;28(9):975-86.
Caicedo RA, Schanler RJ, Li N, Neu J The developing intestinal ecosystem: implications for the neonate. Pediatr Res. 2005 Oct;58(4):625-8. Review.
Caplan MS, Jilling T Neonatal necrotizing enterocolitis: possible role of probiotic supplementation. J Pediatr Gastroenterol Nutr. 2000;30 Suppl 2:S18-22. Review.
Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli FF Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate. 2002 Aug;82(2):103-8.
Deshpande G, Rao S, Patole S Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet. 2007 May 12;369(9573):1614-20. Review.
Gibson GR, Roberfroid MB Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995 Jun;125(6):1401-12. Review.
Guarner F, Malagelada JR Gut flora in health and disease. Lancet. 2003 Feb 8;361(9356):512-9. Review.
Hoyos AB Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis. 1999 Summer;3(4):197-202.
Lidestri M, Agosti M, Marini A, Boehm G Oligosaccharides might stimulate calcium absorption in formula-fed preterm infants. Acta Paediatr Suppl. 2003 Sep;91(441):91-2.
MACGILLIVRAY PC, FINLAY HV, BINNS TB Use of lactulose to create a preponderance of Lactobacilli in the intestine of bottle-fed infants. Scott Med J. 1959 Apr;4(4):182-9.
Mihatsch WA, Hoegel J, Pohlandt F Prebiotic oligosaccharides reduce stool viscosity and accelerate gastrointestinal transport in preterm infants. Acta Paediatr. 2006 Jul;95(7):843-8.
Millar M, Wilks M, Costeloe K Probiotics for preterm infants? Arch Dis Child Fetal Neonatal Ed. 2003 Sep;88(5):F354-8. Review.
Moro G, Arslanoglu S, Stahl B, Jelinek J, Wahn U, Boehm G A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age. Arch Dis Child. 2006 Oct;91(10):814-9. Epub 2006 Jul 27.
Neu J, Caicedo R Probiotics: protecting the intestinal ecosystem? J Pediatr. 2005 Aug;147(2):143-6.
Orrhage K, Nord CE Factors controlling the bacterial colonization of the intestine in breastfed infants. Acta Paediatr Suppl. 1999 Aug;88(430):47-57. Review.
PETUELY F [Lactobacillus bifidus flora produced in artificially-fed infants by bifidogenic substances (bifidus factor)]. Z Kinderheilkd. 1957;79(2):174-9. German.
Rotimi VO, Duerden BI The development of the bacterial flora in normal neonates. J Med Microbiol. 1981 Feb;14(1):51-62.
Sakata H, Yoshioka H, Fujita K Development of the intestinal flora in very low birth weight infants compared to normal full-term newborns. Eur J Pediatr. 1985 Jul;144(2):186-90.
Schumann C Medical, nutritional and technological properties of lactulose. An update. Eur J Nutr. 2002 Nov;41 Suppl 1:I17-25. Review.
Szilagyi A Redefining lactose as a conditional prebiotic. Can J Gastroenterol. 2004 Mar;18(3):163-7. Review.
Uhlemann M, Heine W, Mohr C, Plath C, Pap S [Effects of oral administration of bifidobacteria on intestinal microflora in premature and newborn infants]. Z Geburtshilfe Neonatol. 1999 Sep-Oct;203(5):213-7. German.
Vanderhoof JA, Young RJ Probiotics in pediatrics. Pediatrics. 2002 May;109(5):956-8. Review.
The Effects of Lactulose Supplementation to Enteral Feedings in Premature Infants - A Pilot Study
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.